已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1

嗜睡症 医学 安慰剂 麻醉 艾普沃思嗜睡量表 清醒 猝倒 兴奋剂 多次睡眠潜伏期试验 嗜睡 临床终点 白天过度嗜睡 不利影响 内科学 随机对照试验 睡眠障碍 多导睡眠图 莫达非尼 失眠症 呼吸暂停 药理学 受体 精神科 替代医学 脑电图 病理
作者
Yves Dauvilliers,Emmanuel Mignot,Rafael del Rio-Villegas,Yeting Du,Elizabeth Hanson,Yuichi Inoue,Harisha Kadali,Elena Koundourakis,Seetha Meyer,Raquel Rogers,Thomas E. Scammell,Sarah Sheikh,Todd J. Swick,Zsolt Szakács,Philipp von Rosenstiel,Jingtao Wu,H Zeitz,Naga Venkatesha Murthy,Giuseppe Plazzi,Christian von Hehn
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:389 (4): 309-321 被引量:15
标识
DOI:10.1056/nejmoa2301940
摘要

Narcolepsy type 1 is caused by severe loss or lack of brain orexin neuropeptides.We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1. Patients with confirmed narcolepsy type 1 according to clinical criteria were randomly assigned to receive twice-daily oral TAK-994 (30 mg, 90 mg, or 180 mg) or placebo. The primary end point was the mean change from baseline to week 8 in average sleep latency (the time it takes to fall asleep) on the Maintenance of Wakefulness Test (range, 0 to 40 minutes; normal ability to stay awake, ≥20 minutes). Secondary end points included the change in the Epworth Sleepiness Scale (ESS) score (range, 0 to 24, with higher scores indicating greater daytime sleepiness; normal, <10) and the weekly cataplexy rate.Of the 73 patients, 17 received TAK-994 at a dose of 30 mg twice daily, 20 received 90 mg twice daily, 19 received 180 mg twice daily, and 17 received placebo. The phase 2 trial and an extension trial were terminated early owing to hepatic adverse events. Primary end-point data were available for 41 patients (56%); the main reason for missing data was early trial termination. Least-squares mean changes to week 8 in average sleep latency on the MWT were 23.9 minutes in the 30-mg group, 27.4 minutes in the 90-mg group, 32.6 minutes in the 180-mg group, and -2.5 minutes in the placebo group (difference vs. placebo, 26.4 minutes in the 30-mg group, 29.9 minutes in the 90-mg group, and 35.0 minutes the 180-mg group; P<0.001 for all comparisons). Least-squares mean changes to week 8 in the ESS score were -12.2 in the 30-mg group, -13.5 in the 90-mg group, -15.1 in the 180-mg group, and -2.1 in the placebo group (difference vs. placebo, -10.1 in the 30-mg group, -11.4 in the 90-mg group, and -13.0 in the 180-mg group). Weekly incidences of cataplexy at week 8 were 0.27 in the 30-mg group, 1.14 in the 90-mg group, 0.88 in the 180-mg group, and 5.83 in the placebo group (rate ratio vs. placebo, 0.05 in the 30-mg group, 0.20 in the 90-mg group, and 0.15 in the 180-mg group). A total of 44 of 56 patients (79%) receiving TAK-994 had adverse events, most commonly urinary urgency or frequency. Clinically important elevations in liver-enzyme levels occurred in 5 patients, and drug-induced liver injury meeting Hy's law criteria occurred in 3 patients.In a phase 2 trial involving patients with narcolepsy type 1, an orexin receptor 2 agonist resulted in greater improvements on measures of sleepiness and cataplexy than placebo over a period of 8 weeks but was associated with hepatotoxic effects. (Funded by Takeda Development Center Americas; TAK-994-1501 and TAK-994-1504 ClinicalTrials.gov numbers, NCT04096560 and NCT04820842.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科研通AI6.3的应助被三块石头采纳,获得10
1秒前
南风向北完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
2秒前
梦寐完成签到,获得积分10
2秒前
Eourique发布了新的文献求助10
4秒前
今后的应助被zrl采纳,获得30
4秒前
Lucas的应助被俭朴灵竹采纳,获得10
5秒前
科研通AI6.4的应助被77采纳,获得10
5秒前
古德猫宁发布了新的文献求助10
5秒前
LG发布了新的文献求助10
6秒前
星辰大海的应助被文2026采纳,获得10
6秒前
打打的应助被倾解采纳,获得30
7秒前
飘逸小之发布了新的文献求助10
8秒前
9秒前
9秒前
12秒前
13秒前
整齐半青完成签到 ,获得积分10
14秒前
反反复复发布了新的文献求助10
14秒前
15秒前
15秒前
充电宝的应助被ddl30采纳,获得10
16秒前
ForTune发布了新的文献求助10
16秒前
punch发布了新的文献求助20
17秒前
暖柚完成签到,获得积分10
17秒前
至一完成签到,获得积分10
17秒前
舒适剑发布了新的文献求助10
18秒前
18秒前
不知道叫什么完成签到 ,获得积分10
20秒前
20秒前
春风暮雪发布了新的文献求助10
21秒前
syvshc的应助被洋芋二号采纳,获得10
21秒前
刘辞忧发布了新的文献求助10
21秒前
Lucas的应助被香蕉灵采纳,获得20
21秒前
bkagyin的应助被夏侯乌采纳,获得10
21秒前
W~舞完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184646
求助须知:如何正确求助?哪些是违规求助? 9573637
关于积分的说明 21832477
捐赠科研通 7781914
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003